TCG CROSSOVER MANAGEMENT LLC
Q4 2023 Form 13-F
PALO ALTO, CALIFORNIA
CIK 0001839948
· CRD 311718
· SEC-registered investment adviser
$901.7M Reported Value Total
TCG CROSSOVER MANAGEMENT, LLC reports 2 total accounts under management (AUM). There are 2 discretionary accounts valued at $2,196,110,899, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
3 funds
· $3.8B gross asset value
Other: $3.8B
Source: Form ADV filed 2026-05-29
Reported value
$901.7M
Quarter over quarter
+29.1%
Holdings
29
Top-10 concentration
61.3%
Key People
Form ADV owners & control persons
Chen Ming Yu
MANAGING PARTNER
Craig David Skaling
CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2023 13F record
Q4 2023 13F filing summary
| Period of report | December 31, 2023 |
|---|---|
| Filed | February 14, 2024 |
| Form | 13F-HR |
| Reported value | $901.7M |
| Positions | 29 |
| Change in reported value | +32.8% |
| New positions | 5 |
| Exited positions | 2 |
| Position turnover | 22.6% |
| Top-10 concentration | 61.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
57 | $3.5B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
54 | $4.2B |
|
Q1 2026 13F
Filed May 15, 2026
|
49 | $3.5B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
43 | $3.0B |
|
Q3 2025 13F
Filed Nov 17, 2025
|
40 | $2.0B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
37 | $875.5M |
|
Q1 2025 13F
Filed May 14, 2025
|
37 | $733.1M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
38 | $1.0B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
36 | $1.2B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
32 | $959.5M |
|
Q1 2024 13F
Filed May 15, 2024
|
33 | $1.3B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
29 | $901.7M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
26 | $679.1M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
22 | $609.8M |
|
Q1 2023 13F
Filed May 15, 2023
|
22 | $513.0M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
21 | $566.6M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
21 | $333.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
22 | $235.4M |
|
Q1 2022 13F
Filed May 16, 2022
|
20 | $249.1M |
|
Q4 2021 13F
Filed Feb 18, 2022
|
15 | $213.6M |
Top 20 holdings · Q4 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | GPCR STRUCTURE THERAPEUTICS INC | $86.0M | 9.54% |
| 2 | INBX INHIBRX,INC | $66.5M | 7.38% |
| 3 | ICVX ICOSAVAX INC | $58.4M | 6.47% |
| 4 | ANTX AN2 Therapeutics, Inc. | $54.9M | 6.09% |
| 5 | RYZB RAYZEBIO, INC. | $54.1M | 6.0% |
| 6 | AVTE AEROVATE THERAPEUTICS INC | $49.8M | 5.52% |
| 7 | GERN GERON CORP | $49.3M | 5.47% |
| 8 | SVRA SAVARA INC. | $47.0M | 5.21% |
| 9 | GRCL GRACELL BIOTECHNOLOGIES INC. | $45.3M | 5.03% |
| 10 | MDGL MADRIGAL PHARMACEUTICALS INC | $41.6M | 4.62% |
| 11 | KALV KALVISTA PHARMACEUTICALS, INC | $41.6M | 4.61% |
| 12 | SLN SILENCE THERAPEUTICS PLC | $36.6M | 4.05% |
| 13 | CMPS COMPASS PATHWAYS PLC | $33.8M | 3.74% |
| 14 | COGT COGENT BIOSCIENCES INC | $33.1M | 3.67% |
| 15 | TYRA TYRA BIOSCIENCES INC | $27.5M | 3.06% |
| 16 | TRML TOURMALINE BIO INC | $26.4M | 2.93% |
| 17 | TARS TARSUS PHARMACEUTICALS, INC. | $23.1M | 2.57% |
| 18 | DYN DYNE THERAPEUTICS, INC | $21.9M | 2.43% |
| 19 | KURA KURA ONCOLOGY INC | $20.5M | 2.27% |
| 20 | CNTA CENTESSA PHARMACEUTICALS PLC | $16.2M | 1.8% |
Values as reported on the Q4 2023 Form 13F. Every position is in the holdings table below.